Dry eye/OSD

Nasal spray shows promise in dry eye disease

OC-01 (Varenicline; Oyster Point Pharma) nasal spray was found to significantly reduces goblet cell area and perimeter in dry eye disease (DED), demonstrating goblet cell degranulation, according to data presented at the 2020 AAO Virtual Meeting. Varenicline nasal spray is approved in the United States for smoking cessation and has...